Boston Scientific announced that it has completed enrolment in a first-in-human clinical trial utilising the IntellaTip MiFi XP Ablation Catheter for the treatment of type 1 atrial flutter. This single centre feasibility trial enrolled 10 patients and was led by Prash Sanders, director of the Centre for Heart Rhythm Disorders at the University of Adelaide and the Royal Adelaide Hospital in Australia.
According to a company release, catheter ablation has become a first-line treatment approach for patients with recurrent type 1 atrial flutter and has demonstrated more successful short- and long-term outcomes compared to anti-arrhythmic drug therapy.
The IntellaTip MiFi XP Catheter is the first addition to the IntellaTip family of ablation catheters Boston Scientific expects to unveil over the coming years. A company release states that this new line of ablation catheters is designed to provide physicians with high resolution, precise, multidimensional information through sophisticated micro-sensors at the tip of the catheter.
“The IntellaTip MiFi XP Catheter provided all of the benefits of a large tip catheter while allowing significantly more detailed mapping,” said Sanders. “The catheter handling was intuitive and I found that the mapping capabilities gave me greater ability to identify gaps and know where to ablate. Potentially reflecting this, we had several procedures where the ablation time was quite short compared to conventional ablation technology.”
“We believe the design of the IntellaTip MiFi technology will redefine the quality of critical electrical information that electrophysiologists depend on during ablation procedures,” said Pete Sommerness, general manager, Electrophysiology, Boston Scientific.
The IntellaTip MiFi XP is an investigational device and is not available for sale.